JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by d’Herbomez, M.
Right arrow Articles by Marchandise, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by d’Herbomez, M.
Right arrow Articles by Marchandise, X.
Journal of Nuclear Medicine Vol. 42 No. 7 993-997
© 2001 by Society of Nuclear Medicine


CLINICAL INVESTIGATIONS

Chromogranin A Assay and 131I-MIBG Scintigraphy for Diagnosis and Follow-Up of Pheochromocytoma

Michèle d’Herbomez, Valérie Gouze, Damien Huglo, Marie Nocaudie, François Pattou, Charles Proye, Jean-Louis Wémeau and Xavier Marchandise

Departments of Nuclear Medicine, Endocrine Surgery, and Endocrinology, Center Hospitalier Universitaire de Lille, Lille, France

We assessed the performance of a new serum chromogranin A (CgA) assay in combination with the results of 131I-metaiodobenzylguanidine (MIBG) scintigraphy for diagnosis and follow-up in 89 patients with clinical findings suggestive of pheochromocytoma. Methods: The study population consisted of 41 patients with proven pheochromocytoma and 48 patients with refuted pheochromocytoma. Eighty-seven scintigraphy examinations were performed, 52 in patients with proven pheochromocytoma (39 before surgery and 13 after surgery) and 35 in patients with refuted pheochromocytoma. Results: The sensitivity of the CgA level was 90.2%, and the specificity was 99.0% and 92.3% in the control and refuted pheochromocytoma groups, respectively. A significant relationship was seen between serum levels of CgA and tumor mass (r = 0.70; P < 10-5). The postoperative CgA level was an early and accurate predictor of curative surgery or relapse. The concordance between CgA levels and scintigraphic data was 90.8%. Conclusion: Serum CgA level is an effective marker of pheochromocytoma. Increased levels strongly correlate with tumor mass; therefore, small tumors may go undetected. The concordance between CgA level and the results of 131I-MIBG scintigraphy is high. A CgA level in the reference range is highly predictive of normal scintigraphy findings.

Key Words: pheochromocytoma • 131I-metaiodobenzylguanidine scan • chromogranin A assay




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
M. d'Herbomez, G. Forzy, C. Bauters, C. Tierny, P. Pigny, B. Carnaille, F. Pattou, J.-L. Wemeau, and N. Rouaix
An analysis of the biochemical diagnosis of 66 pheochromocytomas
Eur. J. Endocrinol., May 1, 2007; 156(5): 569 - 575.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein
The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Endocr. Rev., April 1, 2004; 25(2): 309 - 340.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.